Browsing Tag
Genmab A/S
4 posts
Scancell confirms Neuphoria reverse-merger talks as SCLP targets Nasdaq and Phase 3 funding
Scancell is discussing an all-share acquisition of Neuphoria Therapeutics that could secure a Nasdaq listing and strengthen funding options for the global Phase 3 trial of iSCIB1+.
Can Epcoritamab plus R2 become the new second-line standard in follicular lymphoma after Genmab’s Phase 3 success?
Genmab’s Epcoritamab plus R2 combo cut FL relapse risk by 79% in Phase 3. Find out why this bispecific therapy may reshape second-line treatment.
Genmab’s $8bn takeover of Merus: What it means for biotech M&A and the race to control antibody innovation
Find out how Genmab’s $8B acquisition of Merus and its petosemtamab asset is reshaping the oncology biotech race and investor sentiment today.
Genmab’s epcoritamab therapy delivers promising results for relapsed follicular lymphoma
Relapsed or refractory follicular lymphoma (FL) remains a persistent challenge for patients, particularly those with high-risk features. Genmab…